GLYCOMIRA, LLC

Basic Information

675 ARAPEEN DR, STE 302
SALT LAKE CITY, UT, 84108-1228

Company Profile

n/a

Additional Details

Field Value
DUNS: 827444345
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis

    Amount: $199,997.00

    DESCRIPTION (provided by applicant): GlycoMira Therapeutics has developed safe and effective anti-inflammatory glycosaminoglycan derivatives and proposes to test the feasibility of using its lead com ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    Amount: $1,500,000.00

    DESCRIPTION (provided by applicant): Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults. In the most severely affected, progression of th ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    Amount: $1,507,000.00

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of th ...

    SBIR Phase II 2013 Department of Health and Human Services National Institutes of Health
  4. Novel Glycosaminoglycan Ethers for Prevention of Metastasis

    Amount: $210,000.00

    DESCRIPTION (provided by applicant): Heparin and its derivatives block P- and L-selectin mediated metastatic spread of cancer in animal models, and they potently inhibit the matrix degrading enzyme he ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    Amount: $210,000.00

    DESCRIPTION (provided by applicant): Chronic gingival inflammation afflicts over half of all American adults and can progress to periodontal disease, eventually resulting in tooth loss. Periodontitis ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Novel Glycosaminoglycan Derivatives for Treatment of Bladder Inflammation

    Amount: $200,024.00

    DESCRIPTION (provided by applicant): Painful bladder syndrome/interstitial cystitis (PBS/IC) is an indolent bladder disorder that has continued to be a debilitating disease with few truly effective tr ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Sulfated Polysaccharide Derivatives for the Treatment of Rosacea

    Amount: $149,800.00

    DESCRIPTION (provided by applicant): Rosacea is a common disfiguring skin disease affecting 3% of the population over 30 years of age, or 14 million Americans. In men and women of Celtic origin, Rosa ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Sulfated Polysaccharide Derivatives for Treatment of Macular Degeneration

    Amount: $140,000.00

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a leading cause of blindness in the U.S., affecting 8 million Americans over fifty years of age. Its cause is rooted in t ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government